Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(2.71)
# 1,873
Out of 5,147 analysts
91
Total ratings
34.88%
Success rate
9.23%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XOMA XOMA Royalty | Initiates: Buy | $76 | $25.53 | +197.69% | 1 | Dec 9, 2025 | |
| SAVA Cassava Sciences | Initiates: Buy | $8 | $2.28 | +250.88% | 2 | Oct 6, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.67 | +3,852.10% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.33 | +3,551.86% | 1 | Dec 12, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $0.13 | +8,650.99% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $54.81 | -8.77% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.27 | +1,238.58% | 1 | Sep 30, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.09 | +1,184.40% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.68 | +2,400.00% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $43 | $19.69 | +118.38% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.96 | +262.90% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.01 | +642.57% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $3.63 | +313.22% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $6.90 | +450.72% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.88 | +4,437.21% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $6.93 | +621.50% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $5.23 | +3,727.75% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $14.85 | +122.22% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $20.96 | +90.84% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $0.23 | +16,099.65% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $7.95 | +302.52% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $8.23 | +835.60% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.57 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $63.27 | -20.97% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $5.46 | +504.40% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $12.05 | +115.77% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $275.64 | -89.84% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.12 | +16,501.56% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $8.94 | +134.90% | 2 | Jul 12, 2017 |
XOMA Royalty
Dec 9, 2025
Initiates: Buy
Price Target: $76
Current: $25.53
Upside: +197.69%
Cassava Sciences
Oct 6, 2025
Initiates: Buy
Price Target: $8
Current: $2.28
Upside: +250.88%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.67
Upside: +3,852.10%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.33
Upside: +3,551.86%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $0.13
Upside: +8,650.99%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $54.81
Upside: -8.77%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.27
Upside: +1,238.58%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.09
Upside: +1,184.40%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.68
Upside: +2,400.00%
Alto Neuroscience
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $19.69
Upside: +118.38%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $4.96
Upside: +262.90%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.01
Upside: +642.57%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $3.63
Upside: +313.22%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $6.90
Upside: +450.72%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.88
Upside: +4,437.21%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $6.93
Upside: +621.50%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $5.23
Upside: +3,727.75%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $14.85
Upside: +122.22%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $20.96
Upside: +90.84%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $0.23
Upside: +16,099.65%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $7.95
Upside: +302.52%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $8.23
Upside: +835.60%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.57
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $63.27
Upside: -20.97%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $5.46
Upside: +504.40%
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $12.05
Upside: +115.77%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $275.64
Upside: -89.84%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.12
Upside: +16,501.56%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $8.94
Upside: +134.90%